United States - English - NLM (National Library of Medicine)

genentech, inc. - pertuzumab (unii: k16aiq8ctm) (pertuzumab - unii:k16aiq8ctm) - pertuzumab 30 mg in 1 ml - perjeta is indicated for use in combination with trastuzumab and docetaxel for the treatment of patients with her2-positive metastatic breast cancer who have not received prior anti-her2 therapy or chemotherapy for metastatic disease [see dosage and administration (2.2) and clinical studies (14.1)] . perjeta is indicated for use in combination with trastuzumab and chemotherapy for - the neoadjuvant treatment of patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer [see dosage and administration (2.2) and clinical studies (14.2)] . - the adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence [see dosage and administration (2.2) and clinical studies (14.3)] . perjeta is contraindicated in patients with known hypersensitivity to pertuzumab or to any of its excipients. pregnancy pharmacovigilance program there is a pre

Israel - English - Ministry of Health

roche pharmaceuticals (israel) ltd - pertuzumab - concentrate for solution for infusion - pertuzumab 420 mg / 14 ml - pertuzumab - pertuzumab - early breast cancer perjeta is indicated for use in combination with trastuzumab and chemotherapy for: • the neoadjuvant treatment of patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. • the adjuvant treatment of patients with her2-positive early breast cancer (node positive) at high risk of recurrence .metastatic breast cancerperjeta is indicated for use in combination with trastuzumab and docetaxel for the treatment of patients with her2-positive metastatic breast cancer who have not received prior anti-her2 therapy or chemotherapy for metastatic disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - pertuzumab, quantity: 420 mg - injection, intravenous infusion - excipient ingredients: histidine; sucrose; glacial acetic acid; water for injections; polysorbate 20 - early breast cancer perjeta is indicated in combination with trastuzumab and chemotherapy for:,- the neoadjuvant treatment of patients with her2-positive inflammatory or locally advanced, or early stage (either > 2 cm in diameter or node positive) breast cancer as part of a complete treatment regimen for early breast cancer,-the adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence.,metastatic breast cancer,perjeta is indicated in combination with trastuzumab and docetaxel for patients with metastatic her2-positive breast cancer who have not received prior anti-her2 therapy or chemotherapy for their metastatic disease.

European Union - English - EMA (European Medicines Agency)

roche registration gmbh - pertuzumab, trastuzumab - breast neoplasms - antineoplastic agents - early breast cancer (ebc)phesgo is indicated for use in combination with chemotherapy in:the neoadjuvant treatment of adult patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrencethe adjuvant treatment of adult patients with her2-positive early breast cancer at high risk of recurrencemetastatic breast cancer (mbc)phesgo is indicated for use in combination with docetaxel in adult patients with her2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-her2 therapy or chemotherapy for their metastatic disease.

United States - English - NLM (National Library of Medicine)

genentech, inc. - pertuzumab (unii: k16aiq8ctm) (pertuzumab - unii:k16aiq8ctm), trastuzumab (unii: p188anx8ck) (trastuzumab - unii:p188anx8ck), hyaluronidase (human recombinant) (unii: 743quy4vd8) (hyaluronidase (human recombinant) - unii:743quy4vd8) - phesgo is indicated for use in combination with chemotherapy for - the neoadjuvant treatment of adult patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer [see dosage and administration (2.2) and clinical studies (14.2)] . - the adjuvant treatment of adult patients with her2-positive early breast cancer at high risk of recurrence [see dosage and administration (2.2) and clinical studies (14.2)] . select patients for therapy based on an fda-approved companion diagnostic test [see dosage and administration (2.1)]. phesgo is indicated for use in combination with docetaxel for the treatment of adult patients with her2-positive metastatic breast cancer who have not received prior anti-her2 therapy or chemotherapy for metastatic disease [see dosage and administration (2.2) and clinical studies (14.1)] . select patients for therapy based on an fda-approved compa

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

f. hoffmann-la roche ltd - pertuzumab - pertuzumab....600 mg / trastuzumab....600 mg

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

f. hoffmann-la roche ltd - pertuzumab - pertuzumab....1200 mg / trastuzumab....600 mg

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

roche diagnostics gmbh - pertuzumab - concentrate for solution for infusion - 30mg/ml

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - pertuzumab 420mg equivalent to 30 mg/ml - concentrate for infusion - 420 mg/14ml - active: pertuzumab 420mg equivalent to 30 mg/ml excipient: glacial acetic acid histidine polysorbate 20 sucrose water for injection - metastatic breast cancer perjeta is indicated in combination with trastuzumab and docetaxel for patients with her2-positive metastatic breast cancer who have not received prior anti-her2 therapy or chemotherapy for their metastatic disease.

European Union - English - EMA (European Medicines Agency)

roche registration gmbh  - pertuzumab - breast neoplasms - antineoplastic agents, monoclonal antibodies - metastatic breast cancer:perjeta is indicated for use in combination with trastuzumab and docetaxel in adult patients with her2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-her2 therapy or chemotherapy for their metastatic disease.neoadjuvant treatment of breast cancer:perjeta is indicated for use in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence.